首页> 外文期刊>Clinical Epidemiology >Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
【24h】

Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study

机译:在临床流行病学中使用现有数据源:芬兰医疗保健机构在阿尔茨海默氏病研究中注册-阿尔茨海默氏病患者的药物使用情况(MEDALZ-2005)研究

获取原文
       

摘要

Abstract: Memory diseases are the most important determinant of health care service use and quality of life among older individuals. Adverse effects of medication are common among older people, but this age group is underrepresented in clinical trials. Finnish statutory health care and prescription registers, together with personal identification numbers (PINs) and a tax-supported public health plan covering all citizens provide excellent opportunities for epidemiological research. We used routinely collected data from the Finnish health care system to establish the MEDication use among persons with Alzheimer’s disease (MEDALZ-2005) cohort. This cohort study will be used to assess medication use and its effects on health status and hospitalization among persons with Alzheimer’s disease (AD). The cohort includes all community-dwelling persons who had a clinically verified diagnosis of AD, resided in Finland, and were alive on December 31, 2005 and a matched comparison person for each affected individual. Data on purchased prescription medicines (1995–2009), inpatient hospital admissions (1972–2009), outpatient visits (1995–2009), details on diagnosed cancers (1972–2009), and mortality (until October 2010) are available for the whole cohort. This paper describes how this data can be utilized in etiological research and the assessment of health care service use, drug utilization, and associated adverse outcomes in a particularly vulnerable group that is often underrepresented in clinical trials.
机译:摘要:记忆疾病是老年人使用医疗服务和生活质量的最重要决定因素。药物的不良反应在老年人中很常见,但该年龄组在临床试验中的代表性不足。芬兰的法定卫生保健和处方登记簿,以及个人识别码(PIN)和涵盖所有公民的税收支持的公共卫生计划,为流行病学研究提供了绝佳的机会。我们使用了定期从芬兰医疗保健系统收集的数据来确定阿尔茨海默氏病患者(MEDALZ-2005)人群的药物使用情况。这项队列研究将用于评估药物的使用及其对阿尔茨海默氏病(AD)患者的健康状况和住院的影响。该队列包括2005年12月31日在芬兰居住,并在芬兰生存并经临床证实患有AD的所有社区居民,以及每个受影响个体的匹配对照者。整体上可获得有关购买的处方药(1995-2009),住院患者入院(1972-2009),门诊就诊(1995-2009),诊断出的癌症的详细信息(1972-2009)和死亡率的数据(至2010年10月)。队列。本文介绍了如何将这些数据用于病因学研究,以及在临床试验中通常没有充分体现的特别脆弱人群中对卫生保健服务使用,药物利用以及相关不良后果的评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号